Literature DB >> 10398218

Biochemical and molecular correlations in carnitine palmitoyltransferase II deficiency.

G D Vladutiu1.   

Abstract

Carnitine palmitoyltransferase II (CPT II) deficiency is the most common lipid myopathy in adults and is characterized by exercise-induced pain, stiffness, and myoglobinuria. Retrospective analysis of patients with CPT II deficiency has made it possible to correlate the presence of disease-causing mutations in the CPT2 gene with residual CPT activity in muscle. We present evidence that the ratio of CPT II activity to citrate synthase activity in the skeletal muscle of patients presumed to have CPT II deficiency is important for predicting whether the patient has one, two, or no mutations in the CPT2 gene. This finding will assist in the future correlation of the phenotype with the genotype and in identifying manifesting heterozygotes. Copyright 1999 John Wiley & Sons, Inc.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10398218     DOI: 10.1002/(sici)1097-4598(199907)22:7<949::aid-mus23>3.0.co;2-i

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  4 in total

Review 1.  Protein misfolding, aggregation, and degradation in disease.

Authors:  Niels Gregersen; Lars Bolund; Peter Bross
Journal:  Mol Biotechnol       Date:  2005-10       Impact factor: 2.695

2.  Clinically symptomatic heterozygous carnitine palmitoyltransferase II (CPT II) deficiency.

Authors:  Pushpa Raj Joshi; Marcus Deschauer; Stephan Zierz
Journal:  Wien Klin Wochenschr       Date:  2012-11-27       Impact factor: 1.704

3.  Successful orthotopic heart transplantation in CPTII deficiency.

Authors:  Georgianne L Arnold; Jessie Yester; Elizabeth McCracken; Brian D Feingold; Jerry Vockley
Journal:  Mol Genet Metab       Date:  2021-04-28       Impact factor: 4.797

Review 4.  Muscle Carnitine Palmitoyltransferase II Deficiency: A Review of Enzymatic Controversy and Clinical Features.

Authors:  Diana Lehmann; Leila Motlagh; Dina Robaa; Stephan Zierz
Journal:  Int J Mol Sci       Date:  2017-01-03       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.